BioCentury
ARTICLE | Clinical News

FluMist Quadrivalent regulatory update

July 18, 2016 7:00 AM UTC

FDA said the benefits of FluMist Quadrivalent from AstraZeneca to prevent seasonal influenza continue to outweigh the risks. The announcement follows the recommendation last month by the U.S. CDC’s Ad...